Title for MeetingAbstracts
Alphabetical listing of titles
In vivo fate of HIV-1 infected CD4 + T cells: quantitative analysis of the transition to stable latency.
In vivo fungicidal activity of optimized domain III peptides derived from bactericidal/permeability-increasing protein (BPI).
In vivo generation of special CD4-epitopes on CD8+ cells in the development of HIV-infection.
In vivo genetic variability of HIV-2 envelope V3 region.
In vivo genetic variability of the HIV-1 vif-gene.
In Vivo Grepafloxacin (GFX) Pharmacokinetics in Human Neutrophils.
In vivo human placental transfer of nevirapine and protease inihibitors and its detection in amniotic fluid.
In vivo immune responses increase CCR5 mRNA expression in the female genital tract.
In vivo immunization against HIV proteins using gag synthetic peptides: preliminary results.
In Vivo Implication of the Expression of the Global Regulators, agr and sar, for Endovascular Infections.
In vivo induction of CTLs and neutralizing antibodies by a candidate anti-HIV-1 vaccine based on Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs).
In Vivo Induction of SpeA Experession by Invasive M1T1 Group A Streptococcal Isolates: Evidance for the Role of Host Factors in Inducing Expression of Streptococcal Virulence Genes.
In vivo interaction of HIV-1 Rev with an extended Stem I duplex structure of Rev response element RNA.
In Vivo Intracellular and Plasma Pharmacokinetic Parameters to the Combination of Lopinavir/r and Amprenavir in HIV Infected Patients During Salvage Therapy.
In vivo labeling studies with bromodeoxyuridine (BrDU) and 2H-glucose demonstrate differential effects of HIV on lymphocyte and monocyte proliferation, and substantially enhanced lymphocyte proliferation in HIV-infected patients receiving IL-2 therapy.
In vivo macrophage tropism of pathogenic and non-pathogenic molecular clones and recombinants of simian immunodeficiency virus (SIVmac).
In Vivo Metabolism in Rat and Dog of BAY 38-4766-a Novel Nonnucleosidic Inhibitor of Human Cytomegalovirus Replication.
In vivo migration and antiviral activity of transferred HIV-1-specific cytotoxic T cells.
In vivo Myeloid Cell Purging (MYP) as a therapeutic tool in multi-drug resistant (MDR) HIV patients.
In vivo occurrence of drug resistance mutations under prolonged zidovudine treatment in HIV-1 infected patients with asymptomatic and advanced disease.
In vivo passage of HIV-2 EHO in Macaca nemestrina results in persistent infection, disease progression, and altered cellular tropism.
In vivo passage of HIV-2EHO in Macaca nemestrina results in increased virulence.
In vivo persistence of genetically modified, HIV-1-specific syngeneic lymphocytes in HIV-1-discordant identical twins.
In Vivo Pharmacodynamic Activity of a New Carbapenem, Doripenem (DOR), against Multiple Bacteria in a Murine Thigh Infection Model.
In Vivo Pharmacodynamic Activity of AZD2563, the New Oxazolidinone against Multiple Bacterial Pathogens.
In Vivo Pharmacodynamic Activity of Cefditoren (CDTR) Against Streptococcus pneumoniae.
In Vivo Pharmacodynamic Activity of Ceftriaxone against Viridans Streptococci: Implications for Susceptibility Breakpoints.
In Vivo Pharmacodynamic Activity of Daptomycin (DAP) against Multiple Bacterial Pathogens.
In Vivo Pharmacodynamic Activity of Faropenem against Streptococcus pneumoniae.
In Vivo Pharmacodynamic Activity of Garenoxacin against Multiple Bacteria in a Murine Thigh Infection Model.